TriSalus enters $30M standby equity purchase agreement with Yorkville; authorizes up to $4M warrant repurchase

TriSalus Life Sciences, Inc.

Entered Standby Equity Purchase Agreement to sell up to $30M common stock to Yorkville at 96-97% of VWAP.
Paid $25,000 structuring fee and $300,000 commitment fee; registration statement required before sales.
Board authorized repurchase of publicly-held warrants for up to $4 million.
Advances capped by 4.99% ownership limit and 19.99% exchange cap on outstanding stock.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TriSalus Life Sciences, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) valued at up to $30,000,000 (effective 2023-10-02).

Action: entry
Agreement: equity purchase
Counterparty: YA II PN, Ltd. (Yorkville)
Value: up to $30,000,000
Effective: 2023-10-02

Exact text from the filing

On October 2, 2023, TriSalus Life Sciences, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”).

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-106087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.